SCM
LAB icon

Sterling Capital Management’s Standard BioTools LAB Stock Holding History

Sterling Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,526
Closed -$8.76K – 3356
2026
Q1 		$8.76K Sell
9,526
-7,715
-45% -$9.34K ﹤0.01% 2446
2025
Q4 		$22.1K Sell
17,241
-3,413
-17% -$4.58K ﹤0.01% 2175
2025
Q3 		$26.9K Buy
20,654
+12,572
+156% +$16.5K ﹤0.01% 2002
2025
Q2 		$9.7K Buy
8,082
+4,067
+101% +$4.51K ﹤0.01% 2150
2025
Q1 		$4.34K Sell
4,015
-3,377
-46% -$4.74K ﹤0.01% 2242
2024
Q4 		$12.9K Buy
7,392
+6,496
+725% +$12.1K ﹤0.01% 2046
2024
Q3 		$1.73K Buy
+896
New +$1.75K ﹤0.01% 2250
2015
Q4 		– Sell
-27,673
Closed -$224K – 1012
2015
Q3 		$224K Buy
27,673
+10,013
+57% +$158K ﹤0.01% 905
2015
Q2 		$427K Buy
+17,660
New +$557K ﹤0.01% 744

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Sterling Capital Management's LAB Position: Q2 2026 in Review

Sterling Capital Management sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 9,526 shares — an estimated $8.76K sold.

Sterling Capital Management first reported a position in LAB in Q2 2015 and held it in 9 quarters. The position peaked at $427K in Q2 2015. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Sterling Capital Management reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 9,526 Standard BioTools shares in Q2 2026, an estimated $8.76K.
  • Sterling Capital Management first reported a position in Standard BioTools in Q2 2015 and held it in 9 quarters.
  • Sterling Capital Management's Standard BioTools position peaked at $427K in Q2 2015.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.